Cancer Biomarkers: Can We Turn Recent Failures into Success?

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2010 Aug 14

PMID 20705936

Citations 137

Authors

Eleftherios P Diamandis

Affiliations

Soon will be listed here.

Abstract

Disease biomarkers are used widely in medicine. But very few biomarkers are useful for cancer diagnosis and monitoring. Over the past 15 years, major investments have been made to discover and validate cancer biomarkers. Despite such investments, no new major cancer biomarkers have been approved for clinical use for at least 25 years. In the last decade, many reports have described new cancer biomarkers that promised to revolutionize the diagnosis of cancer and the management of cancer patients. However, many initially promising biomarkers have not been validated for clinical use. In this commentary, a plethora of parameters before sample analysis, during sample analysis, and after sample analysis that can complicate biomarker discovery and validation and lead to "false discovery" are discussed. Several examples of biomarker discoveries that were published in high-profile journals are also presented, as well as why they were not validated and the lessons learned from these false discoveries, so that similar mistakes can be avoided in the future.

Citing Articles

ssMutPA: single-sample mutation-based pathway analysis approach for cancer precision medicine.

He Y, Lai J, Wang Q, Pan B, Li S, Zhao X Gigascience. 2024; 13.

PMID: 39704703 PMC: 11659979. DOI: 10.1093/gigascience/giae105.

Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy-A Narrative Review.

Kedzierska M, Bankosz M J Clin Med. 2024; 13(23).

PMID: 39685591 PMC: 11642550. DOI: 10.3390/jcm13237131.

A Novel Scoring System to Predict Acute Radiation Enteritis Recovery in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy: A Southwest China Cohort Study.

Zeng C, Ji J, Huang Y, Peng Y, Zhang X, Yang Z Int J Gen Med. 2024; 17:5907-5919.

PMID: 39678675 PMC: 11645290. DOI: 10.2147/IJGM.S485087.

Cancer Biomarker Concentration Changes During Tumor Progression.

Chatanaka M, Diamandis E EJIFCC. 2024; 35(3):206-209.

PMID: 39507573 PMC: 11536275.

3D Printed Nanosensors for Cancer Diagnosis: Advances and Future Perspective.

Gupta B, Malviya R, Srivastava S, Ahmad I, Rab S, Singh D Curr Pharm Des. 2024; 30(38):2993-3008.

PMID: 39161144 DOI: 10.2174/0113816128322300240725052530.

References

Kyzas P, Loizou K, Ioannidis J . Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005; 97(14):1043-55. DOI: 10.1093/jnci/dji184. View

Kulasingam V, Diamandis E . Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008; 5(10):588-99. DOI: 10.1038/ncponc1187. View

Shulman R . NMR--another cancer-test disappointment. N Engl J Med. 1990; 322(14):1002-3. DOI: 10.1056/NEJM199004053221410. View

Sturgeon C, Duffy M, Hofmann B, Lamerz R, Fritsche H, Gaarenstroom K . National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010; 56(6):e1-48. DOI: 10.1373/clinchem.2009.133124. View

Leman E, Schoen R, Weissfeld J, Cannon G, Sokoll L, Chan D . Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res. 2007; 67(12):5600-5. DOI: 10.1158/0008-5472.CAN-07-0649. View

Michiels S, Koscielny S, Hill C . Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005; 365(9458):488-92. DOI: 10.1016/S0140-6736(05)17866-0. View

Leman E, Cannon G, Trock B, Sokoll L, Chan D, Mangold L . EPCA-2: a highly specific serum marker for prostate cancer. Urology. 2007; 69(4):714-20. DOI: 10.1016/j.urology.2007.01.097. View

Visintin I, Feng Z, Longton G, Ward D, Alvero A, Lai Y . Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008; 14(4):1065-72. DOI: 10.1158/1078-0432.CCR-07-1569. View

Kim J, Skates S, Uede T, Wong K, Schorge J, Feltmate C . Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002; 287(13):1671-9. DOI: 10.1001/jama.287.13.1671. View

10.

Pepe M, Feng Z, Janes H, Bossuyt P, Potter J . Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008; 100(20):1432-8. PMC: 2567415. DOI: 10.1093/jnci/djn326. View

11.

Petricoin E, Ardekani A, Hitt B, Levine P, Fusaro V, Steinberg S . Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359(9306):572-7. DOI: 10.1016/S0140-6736(02)07746-2. View

12.

McIntosh M, Anderson G, Drescher C, Hanash S, Urban N, Brown P . Ovarian cancer early detection claims are biased. Clin Cancer Res. 2008; 14(22):7574. DOI: 10.1158/1078-0432.CCR-08-0623. View

13.

Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L . Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem. 2003; 49(1):1-6. DOI: 10.1373/49.1.1. View

14.

Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T . Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(21):7677-82. PMC: 1140439. DOI: 10.1073/pnas.0502178102. View

15.

Ioannidis J . Microarrays and molecular research: noise discovery?. Lancet. 2005; 365(9458):454-5. DOI: 10.1016/S0140-6736(05)17878-7. View

16.

Diamandis E . Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. Clin Chem. 2003; 49(8):1272-5. DOI: 10.1373/49.8.1272. View

17.

Leman E, Magheli A, Cannon G, Mangold L, Partin A, Getzenberg R . Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate. 2009; 69(11):1188-94. PMC: 3178806. DOI: 10.1002/pros.20963. View

18.

Diamandis E . Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 2004; 96(5):353-6. DOI: 10.1093/jnci/djh056. View

19.

Diamandis E . Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics. 2004; 3(4):367-78. DOI: 10.1074/mcp.R400007-MCP200. View

20.

Sturgeon C, Hoffman B, Chan D, Chng S, Hammond E, Hayes D . National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem. 2008; 54(8):e1-e10. PMC: 5564312. DOI: 10.1373/clinchem.2007.094144. View